H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, Global Cancer Statistics 2020, GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71(3), 209–249 (2021)

Article  PubMed  Google Scholar 

D.S. Chen, I. Mellman, Elements of cancer immunity and the cancer-immune set point. Nature. 541(7637), 321–330 (2017)

Article  CAS  PubMed  Google Scholar 

X. Zhao, S. Subramanian, Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy. Cancer Res. 77(4), 817–822 (2017)

Article  CAS  PubMed  Google Scholar 

L.A. Emens, P.A. Ascierto, P.K. Darcy, S. Demaria, A.M.M. Eggermont, W.L. Redmond, Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. Eur. J. Cancer 81, 116–129 (2017)

Article  CAS  PubMed  Google Scholar 

C. Manegold, A.C. Dingemans, J.E. Gray, K. Nakagawa, M. Nicolson, S. Peters, The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. J. Thorac. Oncol. 12(2), 194–207 (2017)

Article  PubMed  Google Scholar 

T. Hato, A.X. Zhu, D.G. Duda, Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy. 8(3), 299–313 (2016)

Article  CAS  PubMed  PubMed Central  Google Scholar 

E. Tartour, H. Pere, B. Maillere, M. Terme, N. Merillon, J. Taieb, Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 30(1), 83–95 (2011)

Article  CAS  PubMed  Google Scholar 

Y. Huang, J. Yuan, E. Righi, W.S. Kamoun, M. Ancukiewicz, J. Nezivar, Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. U S A 109(43), 17561–17566 (2012)

Article  CAS  PubMed  PubMed Central  Google Scholar 

F.S. Hodi, D. Lawrence, C. Lezcano, X. Wu, J. Zhou, T. Sasada, Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol. Res. 2(7), 632–642 (2014)

Article  CAS  PubMed  PubMed Central  Google Scholar 

J.J. Wallin, J.C. Bendell, R. Funke, M. Sznol, K. Korski, S. Jones, Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat. Commun. 7, 12624 (2016)

Article  CAS  PubMed  PubMed Central  Google Scholar 

E. Allen, A. Jabouille, L.B. Rivera, I. Lodewijckx, R. Missiaen, V. Steri, Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl Med. 9(385), eaak9679 (2017)

Article  PubMed  PubMed Central  Google Scholar 

A.C. Huang, M.A. Postow, R.J. Orlowski, R. Mick, B. Bengsch, S. Manne, T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 545(7652), 60–65 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

B.C. Miller, D.R. Sen, R. Al Abosy, K. Bi, Y.V. Virkud, M.W. LaFleur, Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20(3), 326–336 (2019)

Article  CAS  PubMed  PubMed Central  Google Scholar 

I. Siddiqui, K. Schaeuble, V. Chennupati, S.A. Fuertes Marraco, S. Calderon-Copete, D. Pais Ferreira, Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity. 50(1), 195–211.e10 (2019)

Article  CAS  PubMed  Google Scholar 

D.S. Thommen, V.H. Koelzer, P. Herzig, A. Roller, M. Trefny, S. Dimeloe, A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat. Med. 24(7), 994–1004 (2018)

Article  CAS  PubMed  PubMed Central  Google Scholar 

E.J. Wherry, T cell exhaustion. Nat. Immunol. 12(6), 492–499 (2011)

Article  CAS  PubMed  Google Scholar 

A. Ribas, J.D. Wolchok, Cancer immunotherapy using checkpoint blockade. Science. 359(6382), 1350–1355 (2018)

Article  CAS  PubMed  PubMed Central  Google Scholar 

A. Ribas, Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discov. 5(9), 915–919 (2015)

Article  CAS  PubMed  PubMed Central  Google Scholar 

B. Bengsch, T. Ohtani, O. Khan, M. Setty, S. Manne, S. O’Brien, Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity. 48(5), 1029–1045.e5 (2018)

Article  CAS  PubMed  PubMed Central  Google Scholar 

S.J. Lee, S.Y. Lee, W.S. Lee, J.S. Yoo, J.M. Sun, J. Lee, Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. Invest. New. Drugs 35(6), 782–790 (2017)

Article  CAS  PubMed  PubMed Central  Google Scholar 

C.G. Willett, Y. Boucher, D.G. Duda, E. di Tomaso, L.L. Munn, R.T. Tong, Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J. Clin. Oncol. 23(31), 8136–8139 (2005)

Article  PubMed  Google Scholar 

Q. Li, Y. Wang, W. Jia, H. Deng, G. Li, W. Deng, Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. Clin. Cancer Res. 26(7), 1712–1724 (2020)

Article  CAS  PubMed  Google Scholar 

S. Zhao, S. Ren, T. Jiang, B. Zhu, X. Li, C. Zhao, Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer. Cancer Immunol. Res. 7(4), 630–643 (2019)

Article  CAS  PubMed  Google Scholar 

E. Lanitis, M. Irving, G. Coukos, Targeting the tumor vasculature to enhance T cell activity. Curr. Opin. Immunol. 33, 55–63 (2015)

Article  CAS  PubMed  PubMed Central  Google Scholar 

G.L. Semenza, HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. (1985) 88(4), 1474–1480 (2000)

Article  CAS  Google Scholar 

G.L. Semenza, HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev. 19(1–2), 59–65 (2000)

Article  CAS  PubMed  Google Scholar 

C.G. Kim, M. Jang, Y. Kim, G. Leem, K.H. Kim, H. Lee, VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers. Sci. Immunol. 4(41), eaay0555 (2019)

Article  CAS  PubMed  Google Scholar 

J. Yang, J. Yan, B. Liu, Targeting VEGF/VEGFR to Modulate Antitumor Immunity. Front. Immunol. 9, 978 (2018)

Article  PubMed  PubMed Central  Google Scholar 

C. Zheng, L. Zheng, J.K. Yoo, H. Guo, Y. Zhang, X. Guo, Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. Cell. 169(7), 1342–1356. e16 (2017)

Article  CAS  PubMed  Google Scholar 

K.M. Mahoney, P.D. Rennert, G.J. Freeman, Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov 14(8), 561–584 (2015)

Article  CAS  PubMed  Google Scholar 

S.A. Patel, A.J. Minn, Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. Immunity. 48(3), 417–433 (2018)

Article  CAS  PubMed  PubMed Central  Google Scholar 

M.F. Sanmamed, L. Chen, A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 175(2), 313–326 (2018)

Article  CAS  PubMed  PubMed Central  Google Scholar 

D. Morgensztern, R.S. Herbst, Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer. Clin. Cancer Res. 22(15), 3713–3717 (2016)

Article  CAS  PubMed  Google Scholar 

A. Palazon, P.A. Tyrakis, D. Macias, P. Velica, H. Rundqvist, S. Fitzpatrick, An HIF-1alpha/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. Cancer Cell. 32(5), 669 – 83 e5 (2017)

N.G. Gavalas, M. Tsiatas, O. Tsitsilonis, E. Politi, K. Ioannou, A.C. Ziogas, VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br. J. Cancer 107(11), 1869–1875 (2012)

Article  CAS  PubMed  PubMed Central  Google Scholar